Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA matthew_yurgelun@dfci.harvard.edu.
Matthew B
MB
Yurgelun
Dana-Farber Cancer Institute, Boston, MA.
Elaine
E
Hiller
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Judy E
JE
Garber
D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000208:ethnology / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003376:Counseling; D003466:Cultural Characteristics; D004252:DNA Mutational Analysis; D005006:Ethnicity / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods*; D005828:Genetics, Population; D055106:Genome-Wide Association Study; D006297:Health Services Accessibility; D054625:Healthcare Disparities / Q000208:ethnology; D006801:Humans; D010641:Phenotype; D011237:Predictive Value of Tests; D011379:Prognosis; D044469:Racial Groups / Q000235:genetics; D063505:Racism; D018570:Risk Assessment; D012307:Risk Factors
D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human